Boundless Bio, Inc. (BOLD) vs Kalaris Therapeutics Inc (KLRS)
A side-by-side comparison of Boundless Bio, Inc. and Kalaris Therapeutics Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BOLD
Boundless Bio, Inc.
$2.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
KLRS
Kalaris Therapeutics Inc
$2.76HealthcareDelayed quote: Oct 6, 2026, 3:59 PM EDT
Total return — BOLD vs KLRS
growth of $100 · dividends reinvested · last 3yBOLD -81.8% (-43.3%/yr)KLRS -99.3% (-80.8%/yr)BOLD compounded faster over this window
Log scale — wide-divergence pair
BOLD KLRS
BOLD vs KLRS: by the numbers
- •KLRS is the larger company ($60M vs $58M market cap).
Metrics side by side
Valuation
| Metric | BOLD | KLRS |
|---|---|---|
| P/B ratio | 0.88 | 1.04 |
Profitability
| Metric | BOLD | KLRS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -58.99% | -76.75% |
| ROIC | -43.97% | -52.40% |
Growth (annualized)
| Metric | BOLD | KLRS |
|---|---|---|
| Total return CAGR (5Y) | N/A | -81.13% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.